Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial

Last updated: December 10, 2024
Sponsor: Mayo Clinic
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cancer/tumors

Neoplasms

Uterine Disorders

Treatment

Electronic Health Record Review

Nutritional Assessment

Educational Intervention

Clinical Study ID

NCT06438588
20-012936
20-012936
NCI-2024-03515
  • Ages > 18
  • All Genders

Study Summary

This clinical trial assesses an effective and translatable care model to understand and reduce the adverse effects that cancer patients experience during their treatment therapies and thereby enhance their well-being and quality of life. Excessive immune activation can affect multiple organs with the most common adverse effects being skin rash, diarrhea, colitis, fatigue, hypothyroidism and anorexia. A restrictive calorie diet, mostly of fat and complex carbohydrates, will mimic fasting and increase resiliency to protect patients from the adverse effects of cancer treatments, by managing the adverse side effects of immune checkpoint inhibitors (ICI) treatments in select cancer patients. The fast mimicking diet (FMD) (Xentigen®) is a calorie restrictive, low-calorie, low-protein, high complex carbohydrate, high-fat diet. The FMD program is a plant-based diet program designed to attain fasting-like effects while providing both macro- and micronutrients to minimize the burden of fasting and adverse effects. The FMD consists of 100% ingredients which are generally regarded as safe (GRAS) and comprises mainly of vegetable-based soups and broths, energy bars, energy drinks, cracker snacks, herbal teas, and supplements. Following a FMD may reduce the adverse effects that some cancer patients experience while following immunotherapy treatments.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients undergoing immunotherapy for their first time

  • Age ≥ 18 years

  • Body mass index (BMI) > 19

  • Histological confirmation of advanced stage malignancies (stage 3 or 4) appropriatefor the following types of immunotherapy: PD-1 antibody (nivolumab, pembrolizumab),PD-L1 antibody (atezolizumab, avelumab, durvalumab), CTLA-4 antibody (ipilimumab) orany combination thereof

Exclusion

Exclusion Criteria:

  • Age < 18 years

  • Pregnant women

  • Nursing mothers

  • Persons of childbearing potential who are unwilling to employ adequate contraception

  • Patients will be excluded if they are on insulin due to diabetes (diabetic patientswill be asked to monitor their glucose levels with a continuous glucose monitoring [CGM] device), if they have allergies to any of the components in the FMD, if thereis unacceptable deterioration of their nutritional status and cancer progression

Study Design

Total Participants: 10
Treatment Group(s): 7
Primary Treatment: Electronic Health Record Review
Phase:
Study Start date:
March 06, 2024
Estimated Completion Date:
March 15, 2027

Study Description

PRIMARY OBJECTIVES:

I. Assess the impact of immunotherapy + FMD/Xentigen® on immune related adverse events rates (irAEs) (including immune-mediated colitis).

II. Appraise the impact of immunotherapy + FMD/Xentigen® on the patient's physical function and quality of life.

III. Evaluate the impact of immunotherapy + FMD/Xentigen® on surrogate markers of inflammation (i.e., fecal calprotectin) as a predictive marker of immune-mediated colitis.

OUTLINE:

Patients receive nutrition counseling with a nutritionist over 60 minutes, receive FMD over 4 days for 3 cycles of immunotherapy and educational guidelines for day 5 to transition to a regular diet. Patients undergo blood sample collection throughout the study.

Upon completion of study intervention, patients are followed up at 6 months.

Connect with a study center

  • Mayo Clinic in Florida

    Jacksonville, Florida 32224-9980
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.